All Stories

  1. CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase ...
  2. Optimal scheduling of post-therapeutic follow-up of patients treated for cancer for early detection of relapses
  3. Analysis of survival adjusted for quality of life using the Q-TWiST function: Interface in R
  4. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO)
  5. Are Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis?
  6. Le score de propension, une alternative crédible à la randomisation ?
  7. Body composition and anti-neoplastic treatment in adult and older subjects - A systematic review
  8. A Systematic Review and Meta-Analysis of Double Venous Anastomosis in Free Flaps
  9. What risk of prostate cancer led urologist to recommend prostate biopsies?
  10. Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology
  11. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 -targeted drugs: results from the European EUHER2 cohort
  12. What to expect from molecular tools for non-documented pediatric infectious diseases
  13. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials): Table 2.
  14. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
  15. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I–II trial of radiotherapy/tipifarnib combination
  16. Prediction of Early Breast Cancer Metastasis from DNA Microarray Data Using High-Dimensional Cox Regression Models
  17. Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma
  18. Perception of Lung Cancer among the General Population and Comparison with Other Cancers
  19. Assessment of health status over time by Prevalence and Weighted Prevalence functions: Interface in R
  20. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
  21. Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
  22. Pelvic exenterations for specific extraluminal recurrences in the era of total mesorectal excision: is there still a chance for cure?
  23. Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer – the INNODIAG study
  24. Prospective construction and validation of a prognostic score to identify patients who benefit from third-line chemotherapy for metastatic breast cancer in terms of overall survival: The METAL3 Study
  25. Le rôle des cohortes d’expansion dans les essais de phase I en cancérologie : des recommandations du HUB phase I
  26. Dosimetric comparison between helical tomotherapy and volumetric modulated arc-therapy for non-anaplastic thyroid cancer treatment
  27. Measurement of inter- and intra-observer variability in the routine clinical interpretation of brain 18-FDG PET-CT
  28. Long-term oncological outcome after endoscopic surgery for olfactory esthesioneuroblastoma
  29. Intensity-modulated radiotherapy for laryngeal and hypopharyngeal cancer
  30. The frontal branch of the facial nerve: can we define a safety zone?
  31. RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer
  32. Evaluation of the Lactate-to-N-Acetyl-aspartate Ratio Defined With Magnetic Resonance Spectroscopic Imaging Before Radiation Therapy as a New Predictive Marker of the Site of Relapse in Patients With Glioblastoma Multiforme
  33. Faisabilité et fiabilité de la cœliochirurgie dans les cancers utérins chez les patientes de poids normal
  34. External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer
  35. Dermatofibrosarcoma protuberans: Margins reduction using slow-Mohs micrographic surgery. Experience with 35 patients
  36. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
  37. Place de la radiothérapie dans le traitement conservateur des sarcomes en territoire irradié
  38. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
  39. Role of radiation therapy in the conservative management of sarcoma within an irradiated field
  40. RhoB Promotes Cancer Initiation by Protecting Keratinocytes from UVB-Induced Apoptosis but Limits Tumor Aggressiveness
  41. Prognostic Relevance of Celiac Lymph Node Involvement in Ovarian Cancer
  42. Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study
  43. Conventional Versus Automated Implantation of Loose Seeds in Prostate Brachytherapy: Analysis of Dosimetric and Clinical Results
  44. Quel niveau de risque incite l’urologue à réaliser des biopsies de la prostate ? Analyse rétrospective et multicentrique française
  45. Prognosis and ICU outcome of systemic vasculitis
  46. Instant-quality fluorescencein-situhybridization as a new tool forHER2testing in breast cancer: a comparative study
  47. The β5/focal adhesion kinase/glycogen synthase kinase 3β integrin pathway in high-grade osteosarcoma: a protein expression profile predictive of response to neoadjuvant chemotherapy
  48. Accuracy of intraoperative pathological examination of SLN in cervical cancer
  49. High Endothelial Venule Blood Vessels for Tumor-Infiltrating Lymphocytes Are Associated with Lymphotoxin  -Producing Dendritic Cells in Human Breast Cancer
  50. Determining the Length of Posttherapeutic Follow-up for Cancer Patients Using Competing Risks Modeling
  51. αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I–II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma
  52. Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties
  53. A large retrospective multicenter study of vaginal melanomas
  54. Breast Imaging: Understanding How Accuracy is Measured When Lesion are the Unit of Analysis
  55. The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma
  56. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints’ definitions in cancer clinical trials
  57. RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor
  58. Recurrence risk after Ivor Lewis oesophagectomy for cancer
  59. Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost
  60. Designing group sequential randomized clinical trials with time to event end points using a R function
  61. Maximal Cytoreduction in Patients With FIGO Stage IIIC to Stage IV Ovarian, Fallopian, and Peritoneal Cancer in Day-to-Day Practice
  62. Anatomical correlates for category-specific naming of objects and actions: A brain stimulation mapping study
  63. High endothelial venules (HEVs) in human melanoma lesions
  64. Laparoscopic observation of the diaphragm undersurface in the staging of peritoneal carcinomatosis: comparison of three optical systems
  65. Palliative care
  66. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics
  67. Abstract 725: eIF4E/4eBP-1 as predictive factor(s) of response to EGFR targeted drug in head and neck cancer
  68. Personalised cancer follow-up: risk stratification, needs assessment or both?
  69. Résections rectosigmoïdiennes cœlioscopiques pour endométriose digestive : résultats chirurgicaux et fonctionnels
  70. Single domain antibodies with VH hallmarks are positively selected during panning of llama (Lama glama) naïve libraries
  71. The Prognostic Significance of Lymphovascular Invasion on Biopsy Specimens in Lung Cancer Treated With Definitive Chemoradiotherapy
  72. Brachytherapy in Lip Carcinoma: Long-Term Results
  73. Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer
  74. Retrospective Analysis of Local Control and Cosmetic Outcome of 147 Periorificial Carcinomas of the Face Treated With Low–Dose Rate Interstitial Brachytherapy
  75. Functional testicular evaluation using PET/CT with 18F-fluorodeoxyglucose
  76. Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer
  77. Coregistration of Prechemotherapy PET-CT for Planning Pediatric Hodgkin's Disease Radiotherapy Significantly Diminishes Interobserver Variability of Clinical Target Volume Definition
  78. Formation of the eIF4F Translation-Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors
  79. Laparoscopic pelvic exenteration for gynaecological malignancy: Is there any advantage?
  80. Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary
  81. Postoperative Radiotherapy in Head and Neck Mucosal Melanoma
  82. An R function to non-parametric and piecewise analysis of competing risks survival data
  83. Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer
  84. DNA polymeraseθ up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability
  85. Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis
  86. Detection of local recurrences of limb soft tissue sarcomas: Is magnetic resonance imaging (MRI) relevant?
  87. Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics
  88. Planning Posttherapeutic Oncology Surveillance Visits Based on Individual Risk
  89. Advances in Soil Dynamics Volume 3
  90. Optimization of follow-up timing from study of patterns of first failure after primary treatment. An example from patients with NSCLC: A study of the REACT working group of ESTRO